半量索磷布韦联合全量达卡他韦治疗终末期肾病合并慢性丙型肝炎患者疗效和耐受性评价*

doi:10.3969/j.issn.1672-5069.2024.06.012

实用肝脏病杂志 ›› 2024, Vol. 27 ›› Issue (6): 844-847.doi: 10.3969/j.issn.1672-5069.2024.06.012

半量索磷布韦联合全量达卡他韦治疗终末期肾病合并慢性丙型肝炎患者疗效和耐受性评价^*

乔进, 赵彦, 窦志华

226006 江苏省南通市南通大学附属南通市第三人民医院药学部(乔进,窦志华);院长办公室(赵彦)

收稿日期:2024-05-20 出版日期:2024-11-10 发布日期:2024-11-07
通讯作者: 窦志华,E-mail:zhihuadou@163.com
作者简介:乔进,男,39岁,医学硕士,副主任药师。研究方向:临床药学研究。E-mail:felixjojo@163.com
基金资助:
^*江苏省卫健委重点科研项目(编号:ZD2021061);南通市卫健委青年医学人才科研基金资助项目(编号:WR2017011)

Efficacy and safety of sofosbuvir and dacatavir combination in the treatment of patients with end-stage renal disease and concomitant chronic hepatitis C

Qiao Jin, Zhao Yan, Dou Zhihua

Department of Pharmacy, Third People's Hospital, Affiliated to Nantong University, Nantong 226006, Jiangsu Province, China

Received:2024-05-20 Online:2024-11-10 Published:2024-11-07

摘要/Abstract

摘要： 目的评估索磷布韦联合达卡他韦治疗终末期肾病合并慢性丙型肝炎(CHC)患者的疗效和耐受性。方法 2020年5月～2022年5月我院诊治的接受维持性血液透析治疗的终末期肾病合并CHC患者42例,均接受索磷布韦联合达卡他韦治疗12 w。采用Simmonds基因分型法进行HCV基因型鉴定,定期评估快速病毒学应答(RVR)、治疗结束病毒学应答(ETVR)、停药6个月持续病毒学应答(SVR6)和停药12个月持续病毒学应答(SVR12)。结果本组终末期肾病合并1b、2a、2b和3型HCV感染患者分别为22例、9例、6例和5例;除基因3型感染者SVR6和SVR12为80.0%外,其他各型HCV感染者RVR、ETVR和SVR均为100.0%(P>0.05);在随访12 m,42例患者血清ALT为23(20,38)U/L,AST为21(17,35)U/L,显著低于基线水平【分别为61(42,92)U/L和59(45,83)U/L,P<0.05】,而外周血血小板计数为155(130,194)×10⁹/L,估算的肾小球滤过率(eGFR)为14.9(12.5,17.3)ml/min×1.73 m²,均显著高于基线水平【分别为122(98,141)×10⁹/L和9.3(8.0,11.5)ml/min×1.73m², P<0.05】;在治疗前后,所有患者血清肌酐(sCr)和尿素(BUN)水平无显著性变化(P>0.05);在直接抗病毒药物(DAAs)治疗过程中,出现8种共55例次不良事件,如恶心、疲劳、瘙痒、食欲减退、高钾血症、低血糖、高血压和关节疼痛等,总体耐受性良好,无因不良事件导致治疗非计划终止。结论应用索非布韦联合达卡他韦治疗终末期肾病合并CHC患者疗效可靠,副作用较小,值得扩大临床研究。

关键词: 丙型肝炎, 终末期肾病, 索非布韦, 达卡他韦, 治疗, 安全性

Abstract: Objective The aim of this study was to investigate efficacy and safety of sofosbuvir and dacatavir combination in the treatment of patients with end-stage renal disease (ESRD) and concomitant chronic hepatitis C (CHC). Methods 42 CHC patients with ESRD were encountered in our hospital between May 2020 and May 2022, and all underwent maintenance hemodialysis. DAAs regimen was carried out by sorfosbuvir and dacatavir combination for all patients for 12 weeks and followed-up for 12 months. HCV genotypes was conducted by Simmonds gene typing. Rapid virological response (RVR), end of treatment virological response (ETVR), sustained virologic response six month (SVR6) and SVR12 were recorded. Results Genotypes infected in our series were 1b in 22 cases, 2a in 9 cases, 2b in 6 cases and 3 in 5 cases; except for SVR6 and SVR12 were 80.0% in patients with genotype 3 infection, the RVR, ETVR and SVR6 and SVR12 were all 100.0%(P>0.05) in patients with other three HCV genotype infection; by end of 12 month follow-up, serum ALT level in 42 patients with CHC was 23(20, 38)U/L, AST was 21(17, 35)U/L, both significantly lower than [61(42, 92)U/L and 59(45, 83)U/L, respectively, P<0.05] at baseline, while peripheral blood platelet count was 155(130, 194)×10⁹/L, and estimated glomerular filtration rate (eGFR) was 14.9(12.5,17.3)ml/min×1.73 m², both significantly higher than [122(98, 141)×10⁹/L and 9.3(8.0, 11.5)ml/min×1.73m², respectively, P<0.05] at baseline; there were no significant differences as respect to serum creatinine and urea levels before and after antiviral treatment (P>0.05); during direct antiviral agent (DAA) therapy, incidence of eight adverse events, including nausea, fatigue, itching, anorexia, hyperkalemia, hypoglycemia, hypertension and joint pain occurred in 55 episodes. Conclusion Application of DAA in dealing with patients with ESRD and complicated CHC have a satisfactory efficacy and safety, which warrants further clinical investigation.

Key words: Hepatitis B, End-stage renal disease, Sofosbuvir, Dacatavir, Therapy, Safety

乔进, 赵彦, 窦志华. 半量索磷布韦联合全量达卡他韦治疗终末期肾病合并慢性丙型肝炎患者疗效和耐受性评价^*[J]. 实用肝脏病杂志, 2024, 27(6): 844-847.

Qiao Jin, Zhao Yan, Dou Zhihua. Efficacy and safety of sofosbuvir and dacatavir combination in the treatment of patients with end-stage renal disease and concomitant chronic hepatitis C[J]. Journal of Practical Hepatology, 2024, 27(6): 844-847.

参考文献

[1] Hua R, Kong F, Li G, et al. Alfosbuvir plus daclatasvir for treatment of chronic hepatitis C virus infection in China. Infect Dis Ther, 2023, 12(11):2595-2609.
[2] Boglione L, Cusato J, Pinna SM, et al. Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens. Arch Virol, 2018,163(4):961-967.
[3] Raza MN, Sughra K, Zeeshan N, et al. Recurrence of hepatitis C virus after treatment with pegylated interferon and direct acting antivirals in Punjab Pakistan. Braz J Biol, 2021, 83:e252610.
[4] Reddy YNV, Nunes D, Chitalia V, et al. Hepatitis C virus infection in kidney transplantation-changing paradigms with novel agents. Hemodial Int, 2018, 22(Suppl 1):S53-S60.
[5] Liu CJ, Sheen IS, Chen CY, et al. Ledipasvir/sofosbuvir for patients coinfected with chronic hepatitis C and hepatitis B in Taiwan: follow-up at 108 weeks posttreatment. Clin Infect Dis, 2022, 75(3):453-459.
[6] D'Ambrosio R, Pasulo L, Puoti M, et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. J Hepatol, 2019, 70(3): 379-387.
[7] Graf C, Mücke MM, Dultz G, et al. Efficacy of direct-acting antivirals for chronic hepatitis C virus infection in people who inject drugs or receive opioid substitution therapy: a systematic review and meta-analysis.Clin Infect Dis, 2020, 70(11): 2355-2365.
[8] Sheta SM, El-Sheikh SM, Osman DI, et al. A novel HCV electrochemical biosensor based on a polyaniline@ Ni-MOF nanocomposite. Dalton T, 2020, 49(26): 8918-8926.
[9] Hashem A, Awad A, Shousha H, et al. Validation of a machine learning approach using FIB-4 and APRI scores assessed by the metavir scoring system: A cohort study. Arab J Gastroenterol, 2021, 22(2): 88-92.
[10] Rowe C, Sitch A J, Barratt J, et al. Biological variation of measured and estimated glomerular filtration rate in patients with chronic kidney disease.Kidney Int, 2019, 96(2): 429-435.
[11] 蒋季杰. 现代肾病学. 北京:人民军医出版社,2001:12-13.
[12] 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019年版). 实用肝脏病杂志, 2020, 23(1):S33-S52.
[13] Wu J, Zhou Y, Fu X, et al. The burden of chronic hepatitis C in China from 2004 to 2050: An individual-based modeling study. Hepatology, 2019, 69(4):1442-1452.
[14] Shahid S, Asghar S, Mahmood T, et al. Sofosbuvir and velpatasvir regimen outcome for chronic hepatitis C patients with end-stage renal disease undergoing hemodialysis. Cureus, 2023, 15(9):e45680.
[15] Atsukawa M, Kondo C, Kawano T, et al. Development of interferon-free, direct-acting antivirals treatment for Japanese patients with chronic hepatitis C infection and chronic kidney disease. J Nippon Med Sch, 2021, 88(3):163-170.
[16] Cacoub P, Ahmed SNS, Ferfar Y, et al. Long-term efficacy of interferon-free antiviral treatment regimens in patients with hepatitis C virus–associated cryoglobulinemia vasculitis.Clin Gastroenterol H, 2019, 17(3): 518-526.
[17] Sheahan T P, Sims A C, Leist S R, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun, 2020, 11(1): 222.
[18] Holmes JA, Rutledge SM, Chung RT. Direct-acting antiviral treatment for hepatitis C. The Lancet, 2019, 393(10179): 1392-1394.
[19] Pearlman BL. Direct-acting antiviral therapy for patients with chronic hepatitis C infection and decompensated cirrhosis. Dig Dis Sci, 2024, 69(5):1551-1561.
[20] Hung IFN, Lung KC, Tso EYK, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet, 2020, 395(10238): 1695-1704.

半量索磷布韦联合全量达卡他韦治疗终末期肾病合并慢性丙型肝炎患者疗效和耐受性评价^*

Efficacy and safety of sofosbuvir and dacatavir combination in the treatment of patients with end-stage renal disease and concomitant chronic hepatitis C

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张少博, 张树庚, 刘连新. 免疫治疗肝细胞癌肝移植患者现状和前景展望^*[J]. 实用肝脏病杂志, 2024, 27(6): 801-803.
[2]	郑浩, 张树庚, 王嘉倍, 郭亚飞. 肝移植术治疗肝细胞癌患者肿瘤复发再治疗策略^*[J]. 实用肝脏病杂志, 2024, 27(6): 804-807.
[3]	朱泽斌, 张树庚, 刘连新. 靶向和免疫治疗原发性肝癌:肝移植术前降期治疗应用进展^*[J]. 实用肝脏病杂志, 2024, 27(6): 808-811.
[4]	张天挺, 许晶, 姜正伟, 嵇卉. 丙酚替诺福韦联合肝爽颗粒治疗慢性乙型肝炎患者疗效及其对肝纤维化指标的影响^*[J]. 实用肝脏病杂志, 2024, 27(6): 820-823.
[5]	张丽, 冯禧轩, 刘飞, 延欢欢. 丙酚替诺福韦联合PEG-IFNα-2b治疗慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(6): 824-827.
[6]	何振文, 徐刚, 孟华, 陈辉, 周庆坤. 艾米替诺福韦再治疗低病毒血症的慢性乙型肝炎患者临床疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(6): 828-831.
[7]	朱中华, 胡均贤, 李炎. 索非布韦/达克拉韦治疗CHC患者血清血管性血友病因子和可溶性血管黏附因子1水平变化^*[J]. 实用肝脏病杂志, 2024, 27(6): 836-839.
[8]	张珂瓈, 童静, 李昌平. 接受达拉他韦和阿舒瑞韦治疗的初治基因1b型慢性丙型肝炎患者疗效评价^*[J]. 实用肝脏病杂志, 2024, 27(6): 840-843.
[9]	李靓, 段丽祥, 孙晓红. NucliSens miniMag与QIAamp系统检测血清丙型肝炎病毒RNA效能比较^*[J]. 实用肝脏病杂志, 2024, 27(6): 848-851.
[10]	陈蓉蓉, 蒋黎黎, 曹利华. 自身免疫性肝炎患者血清细胞因子水平变化及其与治疗应答的关系研究^*[J]. 实用肝脏病杂志, 2024, 27(6): 852-855.
[11]	高宇, 杨磊, 胡光明, 孙占虎, 周涛, 肖杰. 自身免疫性肝炎患者血清巨噬细胞迁移抑制因子和白细胞介素-21水平变化及其对治疗应答的影响^*[J]. 实用肝脏病杂志, 2024, 27(6): 866-869.
[12]	武羽, 韩宇星, 徐曼曼, 焦婧然, 杨雪, 段小宛, 陈煜. DRG付费改革背景下慢加急性肝衰竭患者费用盈亏分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 882-886.
[13]	马莉, 顾中盛, 李想. 内镜下套扎联合奥曲肽和埃索美拉唑治疗肝硬化并发食管静脉曲张破裂出血患者临床疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(6): 903-906.
[14]	武文华, 蔡芝芳, 李亚萍, 贾晓黎, 党双锁. 肝动脉化疗栓塞联合射频消融治疗原发性肝癌患者血清炎症因子变化及其对远期生存率的影响^*[J]. 实用肝脏病杂志, 2024, 27(6): 927-930.
[15]	唐浩, 宋文渊, 程千里, 曾凯, 文拔辉. CT三维可视化指导腹腔镜精准肝段切除联合纤维胆道镜取石治疗复杂性肝胆管结石患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(6): 939-942.